Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

…to go it alone on some of these products would require a massive investment in personnel in regulatory, manufacturing, commercial, supply chain, etc.

ENTA is certainly not going to build its own manufacturing facility. The commercialization plan for each program has to be considered separately.

In NASH, ENTA wants to out-license EDP-305 if it looks viable following the interim analysis in the phase-2b trial. ENTA will also presumably seek to out-license EDP-297 after generating more clinical data.

In RSV, ENTA seeks to commercialize EDP-938 in the US and will seek a partner for international markets. The number of RSV prescribers in the US is small enough to make this a reasonable proposition, IMO.

In HBV, ENTA will seek a partner for international markets and may also seek a partner for the US. The approach taken will depend on whether ENTA is able to develop a functional-cure regimen consisting of EDP-514, EDP-721, and generic nuke… or whether ENTA will need to incorporate an agent being developed by another company.

In COVID-19, it’s too early to say what ENTA’s business approach will be, but the RSV program may provide a template if EDP-235 is potent enough to work as monotherapy.